FI972430L - Immunosuppressiivista aktiivisuutta sisältäviä monoklonaalisen vasta-aineen fragmentteja - Google Patents

Immunosuppressiivista aktiivisuutta sisältäviä monoklonaalisen vasta-aineen fragmentteja Download PDF

Info

Publication number
FI972430L
FI972430L FI972430A FI972430A FI972430L FI 972430 L FI972430 L FI 972430L FI 972430 A FI972430 A FI 972430A FI 972430 A FI972430 A FI 972430A FI 972430 L FI972430 L FI 972430L
Authority
FI
Finland
Prior art keywords
monoclonal antibody
antibody fragments
immunosuppressive activity
immunosuppressive
activity
Prior art date
Application number
FI972430A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI972430A7 (fi
FI972430A0 (fi
Inventor
Zoltan Nagy
Damir Vidovic
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of FI972430A7 publication Critical patent/FI972430A7/fi
Publication of FI972430A0 publication Critical patent/FI972430A0/fi
Publication of FI972430L publication Critical patent/FI972430L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI972430A 1994-12-07 1995-11-25 Immunosuppressiivista aktiivisuutta sisältäviä monoklonaalisen vasta-aineen fragmentteja FI972430L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35091594A 1994-12-07 1994-12-07
PCT/EP1995/004648 WO1996017874A1 (en) 1994-12-07 1995-11-25 Monoclonal antibody fragments having immunosuppressant activity

Publications (3)

Publication Number Publication Date
FI972430A7 FI972430A7 (fi) 1997-06-06
FI972430A0 FI972430A0 (fi) 1997-06-06
FI972430L true FI972430L (fi) 1997-06-06

Family

ID=23378740

Family Applications (1)

Application Number Title Priority Date Filing Date
FI972430A FI972430L (fi) 1994-12-07 1995-11-25 Immunosuppressiivista aktiivisuutta sisältäviä monoklonaalisen vasta-aineen fragmentteja

Country Status (19)

Country Link
EP (1) EP0787151A1 (cs)
JP (1) JP2001506122A (cs)
CN (1) CN1168679A (cs)
AR (1) AR002005A1 (cs)
AU (1) AU4256096A (cs)
BR (1) BR9509902A (cs)
CA (1) CA2206471A1 (cs)
CO (1) CO4480041A1 (cs)
CZ (1) CZ172497A3 (cs)
FI (1) FI972430L (cs)
HU (1) HUT77342A (cs)
IL (1) IL116228A0 (cs)
MA (1) MA23739A1 (cs)
NO (1) NO972522L (cs)
PE (1) PE52996A1 (cs)
PL (1) PL320610A1 (cs)
TR (1) TR199501542A2 (cs)
WO (1) WO1996017874A1 (cs)
ZA (1) ZA9510195B (cs)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0893507A1 (en) 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
AU5588099A (en) * 1998-08-28 2000-03-21 Dendreon Corporation Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody
EP1156060B1 (en) * 2000-05-12 2007-06-27 GPC Biotech AG Human peptides/proteins causing or leading to the killing of cells including lymphoid tumor cells
EP1156062A1 (en) * 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins
US7521047B2 (en) 2000-05-12 2009-04-21 Gpc Biotech Ag Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
US6894149B2 (en) 2001-10-11 2005-05-17 Protein Design Labs, Inc. Anti-HLA-DA antibodies and the methods of using thereof
US7262278B2 (en) 2001-10-15 2007-08-28 Kirin Beer Kabushiki Kaisha Anti-HLA-DR antibody
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
CA2794499A1 (en) * 2010-04-01 2011-10-06 Immumomedics, Inc. Antibody-based depletion of antigen-presenting cells and dendritic cells
KR102647825B1 (ko) * 2021-07-22 2024-03-14 서울대학교산학협력단 항-hla-dp 단클론 항체 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068790B1 (en) * 1981-06-25 1986-02-26 The Board Of Trustees Of The Leland Stanford Junior University Allele specific immunotherapeutic method and dosage form
DE69028713T3 (de) * 1989-12-27 2004-05-13 Centocor, Inc. Schimäre immunoglobuline für cd4-rezeptoren
ES2196002T3 (es) * 1991-07-25 2003-12-16 Idec Pharma Corp Anticuerpos recombinantes para terapia humana.

Also Published As

Publication number Publication date
BR9509902A (pt) 1997-10-21
AR002005A1 (es) 1998-01-07
AU4256096A (en) 1996-06-26
JP2001506122A (ja) 2001-05-15
CA2206471A1 (en) 1996-06-13
TR199501542A2 (tr) 1996-07-21
PL320610A1 (en) 1997-10-13
EP0787151A1 (en) 1997-08-06
CN1168679A (zh) 1997-12-24
NO972522L (no) 1997-08-06
IL116228A0 (en) 1996-03-31
FI972430A7 (fi) 1997-06-06
FI972430A0 (fi) 1997-06-06
NO972522D0 (no) 1997-06-03
ZA9510195B (en) 1996-06-07
WO1996017874A1 (en) 1996-06-13
CZ172497A3 (en) 1997-10-15
MX9704225A (es) 1997-09-30
HUT77342A (hu) 1998-03-30
PE52996A1 (es) 1996-12-12
MA23739A1 (fr) 1996-07-01
CO4480041A1 (es) 1997-07-09

Similar Documents

Publication Publication Date Title
PT719859E (pt) Anticorpo monoclonal anti-alfa v-integrina
DK1516629T3 (da) Humaniseret anti-CD-11a antibodies
DK145493D0 (da) Antistof
IL128406A0 (en) Monoclonal antibodies
DE69920897D1 (de) Monoklonale antikörper mit verringerter immunisierungsfähigkeit
DK666389D0 (da) Monoklonalt antistof
FI964845L (fi) CD44v6:n vastaiset monoklonaaliset vasta-aineet
FI945865A7 (fi) Glykoprofeiini P:lle kohdistettuja monoklonaalisia vasta-aineita
DE69738312D1 (de) Hepatitis b monoklonale antikörper
FI972430L (fi) Immunosuppressiivista aktiivisuutta sisältäviä monoklonaalisen vasta-aineen fragmentteja
FI895287A7 (fi) Fukosyylikeramidin vastainen monoklonaalinen vasta-aine
DE69427850D1 (de) Monoklonaler antikörper gegen mucoglykoprotein
DE69023717D1 (de) Monoklonaler Antikörper.
DE69020315D1 (de) Monoklonaler antikörper gegen c-reaktives protein.
BR9709080A (pt) Anticorpo monoclonal anti-MP52 humano
DE69324928D1 (de) Monoklonaler antikörper
NO20000079D0 (no) Ancrod spesifikke monoklonale antistoff, antistoff- fragmenter, blandinger, derivater og anvendelse derav
HK1001864A (en) Monoclonal antibody fragments having immunosuppressant activity
GB9615027D0 (en) Monoclonal antibodies
ZA954678B (en) Monoclonal antibody against cd44v6
BR1100555B1 (pt) anticorpos monoclonais humanizados.
DK220688D0 (da) Monoklonalt antistof